Clinical-stage immuno-oncology company Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has reported encouraging early response ...
FDA cleared acalabrutinib plus venetoclax as the only all-oral, fixed-dose combination option for first-line, treatment-naïve CLL/SLL. Phase 3 AMPLIFY showed superior PFS versus chemoimmunotherapy, ...
The approval was based on the AMPLIFY trial, which evaluated acalabrutinib alongside venetoclax in adults with previously untreated CLL without del(17p) or TP53 mutation.
The data also show how the economic burden of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is increasing. New data suggest patients who receive a diagnosis of chronic lymphocytic ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Matthew S. Davids, MD, said data from the BRUIN-313 trial supports front-line approval ...
Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...
The US Food and Drug Administration (FDA) has granted accelerated approval for lisocabtagene maraleucel (liso-cel) for the treatment of certain adults with relapsed or refractory chronic lymphocytic ...
Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...
Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...
Jaypirca showed superior PFS and lower discontinuation rates compared to standard treatments in CLL/SLL patients. Jaypirca reduced the risk of progression or death by 46% to 52% and had a favorable ...
Please provide your email address to receive an email when new articles are posted on . In the BRUIN CLL-313 trial, researchers compared pirtobrutinib (Jaypirca, Eli Lilly & Co.) vs. bendamustine plus ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results